Upcoming events
Discussion on the IPF Landscape with Ahmed Mousa and Dr. Francesco Bonella
Previous presentations
44th Annual J.P. Morgan Healthcare Conference
Jefferies Global Healthcare Conference in London
Stifel 2025 Healthcare Conference
Guggenheim’s Second Annual Healthcare Innovation Conference
Morgan Stanley 23rd Annual Global Healthcare Conference
Wells Fargo Healthcare Conference 2025
Cantor Global Healthcare Conference 2025
Biotech2050 Podcast Featuring Vicore CEO Ahmed Mousa
In this episode of Biotech2050, Vicore CEO Ahmed Mousa joins host Alok Tayi to discuss Vicore’s mission to develop a first-in-class therapy targeting the angiotensin II type 2 receptor—offering new hope for patients with idiopathic pulmonary fibrosis, a disease with few effective treatments. The conversation also touches on the opportunities in global biotech leadership, the path to late-stage development, and how a relentless focus on patients drives innovation at Vicore.
H.C. Wainwright & Co - HCW @ Home with Vicore Pharma (VICO.se), May 23 2025
Leerink Partners Global Healthcare Conference 2025, March 11 2025
TD Cowen 45th Annual Health Care Conference, March 4 2025
Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 12 2025
Aktiespararna Life Sciences Event, January 29 2025 (Swedish only)
Webinar: Final Phase 2a AIR trial results
Demonstrating improved lung function with buloxibutid over 36 weeks in patients with IPF. Results presented by Professor Toby Maher.